28 citations
,
September 2016 in “Future oncology” Adverse events from vismodegib can be managed effectively to ensure optimal treatment.
25 citations
,
January 2021 in “Journal of drugs in dermatology” Sonidegib and vismodegib are similarly effective for advanced basal cell carcinoma, but sonidegib might have a slightly better safety profile.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
3 citations
,
May 2025 in “Frontiers in Pharmacology” Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
1 citations
,
July 2018 in “Dermatologic Surgery” Different tumor cells in one basal cell carcinoma can cause mixed treatment responses, suggesting personalized treatment is needed.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
105 citations
,
October 2018 in “Nature” A small group of slow-growing cells causes basal cell carcinoma to return after treatment.
105 citations
,
April 2014 in “Trends in Pharmacological Sciences” Targeting the Smoothened receptor shows promise for treating certain cancers.
88 citations
,
July 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
44 citations
,
September 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
19 citations
,
April 2014 in “Expert opinion on emerging drugs” New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.
17 citations
,
June 2017 in “British Journal of Dermatology” The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.
16 citations
,
March 2015 in “Clinical Cancer Research” The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
15 citations
,
October 2014 in “Journal of Investigative Dermatology” New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.
9 citations
,
December 2014 in “British Journal of Dermatology” Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.
7 citations
,
March 2023 in “Lasers in Surgery and Medicine” Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.
5 citations
,
January 2013 in “Journal der Deutschen Dermatologischen Gesellschaft” The document concludes that individualized treatment for malignant epithelial tumors is necessary and more research on metastatic squamous cell carcinoma treatments is needed.
4 citations
,
January 2019 in “Dermatologic Therapy” Scalp basal cell carcinoma may be more aggressive and harder to treat than other types, requiring special attention and further research.
4 citations
,
January 2016 in “Dermatology Review” Cancer treatments often cause skin, nail, and hair problems.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
1 citations
,
November 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Mohs micrographic surgery is effective for treating basal cell carcinoma on the eyelid, while radiotherapy has higher recurrence rates, and topical vitamin D3 may reduce and delay BCC formation in mice.
March 2026 in “Pharmaceuticals” Reporter characteristics affect detection of hair loss from cancer therapy.
May 2024 in “Deleted Journal” Cancer treatments can cause hair loss, but it is often reversible and can be managed with scalp cooling and support.
December 2023 in “Communications biology” Targeting the HEDGEHOG-GLI1 pathway could help treat keloids.
May 2023 in “Research Square (Research Square)” Blocking the HEDGEHOG-GLI1 pathway can reduce keloid growth and may be a potential treatment.
Hedgehog signaling can create new hair follicles in adult skin but may increase cancer risk.
June 2019 in “International journal of dermatology and venereology” The Hedgehog Signaling Pathway is important for skin and hair development and skin cancer treatment, but more research is needed to understand it fully.
January 2008 in “Projeto: revista mensal de arquitetura” Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.